Oncology Perspective

 
 

  • Medscape Physician Lifestyle & Happiness Report 2022 More than 10,000 physicians in various specialties told Medscape how they are faring amid the global pandemic.
  • Dr. Glaucomflecken on Why We Can All Use a Laugh Right Now   Two bouts with cancer and a cardiac arrest at age 35 haven't stopped this ophthalmologist-comedian from becoming a social media phenomenon for hilariously poking fun at medicine and himself.
  • 5 Things: Lessons I've Learned From Dance Medical student Marshall Hall reflects on how his love of dance has shaped him as a person.
  • Under the Surface, a Reflection on the Movie 'Encanto' Going to the movies with my son reminded me of the value of art and entertainment in our lives, and that it's okay to take a break from our burdens--something that's been missing during this pandemic.
  • Highlights in Acute Lymphoblastic Leukemia From ASH 2021   Highlights in acute lymphoblastic leukemia from ASH 2021 include pediatric regimens for adults, CNS involvement, and a possible transplant-sparing regimen, as reported by Dr Mark Litzow.
  • Keep the Face-Eating Monster at Bay People say they want a cure for cancer. Then why won't they use what we give them?
  • Key Reports in Lymphoma CAR T Therapies From ASH 2021   Key results in CAR T therapies from ASH 2021 focus on shifting from their standard third-line use to second-line use in patients with large B-cell lymphoma, as reported by Dr David Miklos.
  • Advances in Multiple Myeloma From ASH 2021   Bispecific antibodies take center stage in multiple myeloma highlights from ASH 2021, as Dr Amrita Krishnan discusses data on cevostamab, talquetamab, elranatamab, and talquetamab plus daratumumab.
  • COVID Breakthrough Infections and Reinfections: Where We Stand   Drs Angela Rasmussen, Kartik Cherabuddi, and Peter Antevy discuss COVID reinfections and breakthrough infections, as well as the Omicron variant.
  • Top Findings in Myelodysplastic Syndromes From ASH 2021   Key studies in myelodysplastic syndromes at ASH 2021 examine TP53-mutant disease, an all-oral therapy for high-risk patients, and treatments targeting IDH, as presented by Prof Uwe Platzbecker.
  • Top Data in Mantle Cell Lymphoma From ASH 2021   Highlights in mantle cell lymphoma from ASH 2021 include updates from the MCL Younger and Elderly trials, Gpt combo regimens in patients with R/R MCL, the prognostic value of MRD, and real-world experience of brexu-cel therapy.
  • Top 5 Developments in Lung Cancer in 2021   Advances in gene targets and their treatments dominated the therapeutic landscape for 2021, says Dr Mark Kris.
  • Advances in Metastatic Breast Cancer From SABCS 2021   Developments in metastatic breast cancer from SABCS 2021 include new drugs for ER-positive and triple-negative disease, as well as new uses of immunotherapy, as reported by Dr Harold Burstein.
  • Early Breast Cancer Highlights From SABCS 2021   Developments in early breast cancer from SABCS 2021 include refinement of adjuvant therapy in HR-positive disease and positive data on immunotherapy of TNBC, as reported by Dr Ann Partridge.
  • CLL Updates From ASH 2021   CLL highlights from ASH 2021 focus on frontline venetoclax regimens, zanubrutinib in high-risk CLL, promising data on pirtobrutinib in relapsed/refractory disease, and COVID-19 vaccination responses.
  • Pembrolizumab +/- Chemotherapy: Reading Between the Studies   Dr Mark Kris discusses how to read between the studies to determine optimal treatments for patients when clinical trial data are not available.
  • Medscape Nurse Career Satisfaction Report 2021 In a year of upheaval and uncertainty, we asked nurses about the impact of the pandemic, the rising incidence of workplace abuse, and what they think of their chosen professions.
  • How Can You Do This? When the Patient's Family Dictates Care A cancer patient in is agony because a spouse refuses any pain medication. How one oncologist was told they could do nothing.
  • Germline Signatures of Toxicity: A Fertile Field   Dr David Kerr discusses a recent genome-wide association study conducted to investigate germline signatures of toxicity.
  • 2021 in Review   Eric Topol and Abraham Verghese reflect on 2021's extraordinary podcast guests, and how we excelled in science and healthcare but were tripped up by the vagaries of human behavior.